Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs MasterCard Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while MasterCard Inc trades at $563.02 (market cap $491.83B). The key difference: MasterCard Inc is far larger — about 16.6× Alnylam Pharmaceuticals, Inc.'s market cap, and MasterCard Inc pays a 0.62% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MA | |
|---|---|---|
Market Cap | $29.60B | $491.83B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $598.96 |
52-Week Low | $205.48 | $471.55 |
Enterprise Value | $27.56B | $504.86B |
Volume | — | 4,635,698 |
Dividend Yield | — | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Mastercard (MA) trades at $561.44, down 0.31% on the day, with strong technical momentum showing bullish moving averages and key support at $559. The company demonstrates exceptional fundamentals with 46.34% net income margins and consistent earnings beats, including Q2 2026 EPS of $5.04 beating expectations of $4.77. Revenue growth remains robust, increasing from $22.2B in 2022 to $32.8B in 2025, while maintaining profitability above 44%.
Mastercard presents a compelling investment case with 79% analyst buy ratings and a $660.85 consensus price target representing 18% upside. However, elevated valuation ratios (P/E 30.88, P/S 14.31) and emerging payment technology competition from stablecoins present risks. The stock's strong institutional ownership growth and consistent cash flow generation support long-term bullish sentiment despite near-term valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
